Patent intelligence · US
US 8546331
Modulation of pathogenic CD14+/CD16+ monocytes
Modulation of pathogenic CD14+/CD16+ monocytes
Patent details — US 8546331
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 1, 2013
- Expiration
- Sep 26, 2033
- Applicant
- XBIOTECH INC.
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61P, A61P1/04
Quick answer
US 8546331 (Modulation of pathogenic CD14+/CD16+ monocytes) is held by XBIOTECH INC.. Status: granted. Granted Oct 1, 2013. Expires Sep 26, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- XBIOTECH INC.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61P, A61P1/04, A61P19/02, A61P19/10
More from XBIOTECH INC.
Related pharmaceutical patents in our USPTO index.
-
US 12116405
Arthritis treatment
granted -
US 11932688
Treatment for neoplastic diseases
granted -
US 11773157
Compositions and methods for treating and preventing Staphylococcus aureus infections
granted -
US 11529298
Cosmetic composition and its use, dermocosmetic formulation
granted -
US 11523981
Cosmetic composition and its use, dermocosmetic formulation
granted -
US 11370831
Compositions and methods for treating and preventing Staphylococcus aureus infections
granted -
US 10577410
Compositions and methods for treating and preventing Staphylococcus aureus infections
granted -
US 10294296
Treatment for neoplastic diseases
granted
Frequently asked questions
What is US patent 8546331?
US 8546331 (Modulation of pathogenic CD14+/CD16+ monocytes) is held by XBIOTECH INC.. Status: granted. Granted Oct 1, 2013. Expires Sep 26, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8546331?
XBIOTECH INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 31 pharmaceutical patents for this assignee.
When does US 8546331 expire?
Our index shows an expiration date of Sep 26, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.